C
UP is a common clinical syndrome, representing many types of cancers, and in the United States it accounts for approximately 3% of all advanced cancers annually. 1 Although anatomic primary tumor sites are not clinically detectable during life, autopsy "series" documented primaries, usually very small, in approximately 75% of patients with CUP. 2 Most patients with have carcinomas, and adenocarcinomas are the most common histology.
The biology of CUP is a puzzle. The mechanism explaining how a very small primary tumor has the capacity to produce larger clinically detectable metastases, although the primary tumor remains small and clinically undetectable, is an enigma. There are no data yet revealing any genetic aberrations unique to CUP. The genetic profıles of CUP seem to match fairly well to the occult primary tumor sites present in the majority of these patients. Comparisons of CUP with their counterparts with known primary tumors has been diffıcult in the past, but are now possible with the improved diagnostic methods available to determine the tissue of origin in these patients. Although no specifıc genetic markers have been found to explain the biology of CUP, the rapid development of genomic analysis may reveal the molecular mechanisms of this clinicopathologic syndrome in the future.
CUP is defıned as the presence of cancer without a clinically detectable anatomic primary tumor site of origin. The ability to accurately determine the tissue of origin has improved substantially by new diagnostic technologies. Global agreement of the diagnostic tests required at the time of clinical presentation is lacking, but becoming clearer. Most biopsies from these patients are carcinomas, and, rarely, other lineages are eventually diagnosed (lymphoma, melanoma, sarcoma). The management of patients with CUP has changed with the potential to diagnose the tissue of origin and treat with site-specifıc regimens.
DIAGNOSTIC ROLE OF IMMUNOHISTOCHEMISTRY (IHC) AND GENE-EXPRESSION PROFILING
The emergence of more precise IHC marker stains and gene expression/molecular profıling assays has changed the diagnostic approach. [3] [4] [5] The identifıcation of the tissue of origin in CUP is now more important than in the past, since the therapy for patients with many known advanced solid tumors has improved over the past several years. Furthermore, the stakes are likely to be even higher in the future, since more patients with CUP will have improved outcomes when treated with site-specifıc regimens effective for their particular tumor type.
Diagnosis of the tissue of origin in CUP has improved by the application of panels of IHC stains and molecularprofıling assays. Several rather specifıc IHC stains are available today. The IHC stains chosen for the initial diagnostic biopsy is based on the clinical fındings, histologic diagnosis, and knowledge of the common occult tumors presenting as CUP with relatively diagnostic IHC profıles. Screening with selected staining is recommended on most biopsies (see Evaluation and Management in 2013 section) but indiscriminate use of multiple stains is expensive, it frequently exhausts the biopsy specimen, and is often not more revealing than a measured and rational step-wise approach.
Additional pathologic and clinical testing may be indicated, depending on the initial clinicopathologic fındings. Several IHC staining profıles are highly suggestive of particular primary tumor types, but substantial variability remains. For example, false positives and negatives are well appreciated, and the absence of thyroid transcription factor-1 (TTF-1) or CDX-2 positivity in a minority of lung and colon adenocarcinomas, respectively, is well known. There are many different subsets within each category of specifıc carcinomas. Breast cancers are an example of heterogeneity in which staining for ER, PR, and HER2/neu may be positive, negative, or mixed. Further details regarding IHC are discussed later.
Gene-expression profıling assays to determine the tissue of origin in CUP have emerged in the last several years. Several commercial assays are available. 5 The clinical value of these assays in CUP has been diffıcult to prove, but substantial data now validate the relative accuracy in predicting the tissue of origin. [6] [7] [8] [9] [10] [11] [12] [13] [14] The 92 gene reverse transcription polymerase chain reaction molecular profıle assay is approximately 80% accurate in predicting the tissue of origin in CUP, as has been reported by using several correlative methods, and this accuracy is similar to that reported by the three commercially available molecular profıle assays in known advanced primary cancers. 5, 9, [11] [12] [13] [14] Molecular assays complement standard pathology by providing a single diagnosis of the tissue of origin in most patients when diagnostic IHC staining is otherwise inconclusive.
Recently a large prospective study has been completed in CUP, looking at the outcomes or survival of patients treated with site-specifıc or customized therapies based on the molecular assay tissue of origin diagnosis. 15 In 98% of tumors with successful assays, a single tissue of origin was predicted. A total of 194 patients received site-specifıc treatment. The median survival was 12.5 months, compared with the expected survival for patients with CUP receiving the same empiric therapy of about 9 months. 1 Furthermore, the survival of 115 patients with molecular diagnoses of more responsive tumors (colorectal, breast, ovary, kidney, prostate, bladder, non-small cell lung cancer [NSCLC] , germ cell, poorly differentiated neuroendocrine tumor, lymphoma, and small cell lung cancer) was signifıcantly longer (13.4 months compared with 7.4 months; p ϭ 0.04) than the 79 patients with less responsive tumors (biliary tract, pancreas, gastroesophageal, liver, melanoma, sarcoma, cervix, carcinoid, endometrium, mesothelioma, skin, thyroid, head and neck, and adrenal). Survival of patient subsets of molecularly diagnosed tumor types were as follows: biliary tract 6.8 months, pancreas 8.2 months, urothelium 8.4 months, renal 11.7 months, colorectal 12.5 months, NSCLC 15.9 months, ovarian 29.6 months, breast longer than 24 months (not yet reached). There is a survival advantage in CUP when patients receive sitedirected therapy based on the molecular diagnosis, rather than the administration of empiric standard regimens (such as paclitaxel/carboplatin or gemcitabine/cisplatin) to all patients. Many of the molecularly diagnosed cancer types have relatively unresponsive tumor types to any chemotherapy, making the recognition of the more treatable or more responsive tumor types even more critical.
Data from several retrospective and prospective studies [6] [7] [8] 10, [14] [15] [16] [17] [18] show that gene-expression profıling with any of the three commercially available assays of the biopsy specimen will provide a relatively accurate diagnosis of the tissue of origin. As discussed previously, customized or sitespecifıc therapy in patients directed by the molecular diagnosis improves survival compared with empiric chemotherapy. All the clinicopathologic fındings should be considered in conjunction with the molecular assay result, and this process improves the overall accuracy of tissue of origin prediction. The diagnosis of the tissue of origin in patients with CUP has changed the management for the majority of these patients.
EVALUATION AND MANAGEMENT IN 2013
An approach to the diagnosis in patients with suspected CUP is illustrated in Fig.1 . An excisional, incisional, or core needle biopsy is necessary before continuing a more extensive evaluation. The clinical fındings and histology of the
KEY POINTS
⅐ Cancer of unknown primary site (CUP) is a common clinicopathologic syndrome accounting for approximately 3% of cancer diagnoses in the United States annually. ⅐ Historic treatment of patients with CUP has generally been with empiric chemotherapy with poor overall outcome as the tissue of origin could not be determined in most patients. ⅐ Diagnostic technology has recently improved, particularly immunohistochemistry and molecular tumor profiling, enabling a tissue-of-origin diagnosis in most patients. ⅐ Patients with CUP who received site-specific treatment directed by molecular tumor assay diagnosis had improved survival compared with empiric chemotherapy, and those predicted to have more responsive tumor types had longer survival. ⅐ The use of molecular profile assays in CUP represents an improved diagnostic test but requires clinical judgment to interpret the results and determine the optimal management for patients with this complex syndrome.
biopsy specimens suggest that additional clinical and/or specialized pathology testing is indicated. The evaluation initially recommended is outlined in Table 1 . PET scanning may be useful in the evaluation of CUP, but with the exception of squamous cell carcinoma involving cervical lymph nodes, prospective data supporting primary site detection in large numbers of patients are lacking. Additional testing to attempt to fınd the anatomic tumor primary site or the tissue of origin is frequently suggested by the clinicopathologic fınd-ings. Table 2 lists additional supplemental-directed evaluation based on several initial clinicopathologic fındings. The gender of the patient and sites of metastasis are important to consider. The sites of metastasis in CUP as proven by necropsy series, in which the primary tumor site is identifıed, are often atypical for these primaries. For example, occult prostate carcinoma more often spreads to lymph nodes and/or lung initially than to bone; occult pancreatic carcinomas metastasize initially to bone and/or lung more often than expected from known pancreatic carcinoma. However, most occult primary carcinomas metastasize to regional nodes and to other typical well-appreciated sites in a fashion similarly to their counterparts with known primary cancers. The gender and metastatic sites are not specifıc but help in some patients in narrowing the diagnostic possibilities. Examples include • Additional clinical evaluation and specialized testing of the biopsy based on clues from history, physical examination, laboratory testing, medical imaging, and pathology (Table 2) Abbreviations: CUP, cancer of unknown primary site; CBC, complete blood count; CMP, comprehensive metabolic panel; LDH, lactate dehydrogenase; UA, urine analysis; PSA, prostate-specific antigen.
IMPROVED DIAGNOSIS IN UNKNOWN PRIMARY CANCER
asco.org/edbook | 2013 ASCO EDUCATIONAL BOOKlung to mediastinal/hilar nodes/bone/brain, breast to nodes/ liver/bone/skin/lung, kidney to nodes/bone/lung, colorectal to liver/peritoneal cavity, ovary to peritoneal cavity, etc. The sites of metastasis suggest that occult primaries may be present and help to decide which additional clinical testing and IHC staining to perform. Clues should be further investigated. For example, in patients with occult blood in the stool should undergo colonoscopy and gastroduodenoscopy. Women presenting with isolated axillary adenopathy and normal mammograms should have an MRI of the breasts and IHC breast staining performed. In patients with large liver lesions and no other detectable metastasis, serum alphafetoprotein and a tumor Hepar-1 stain are indicated.
The ability to make a diagnosis of the tissue of origin facilitates a more specifıc therapy for each patient. The clinical setting (including gender, historic details, sites of metastasis, laboratory and medical imaging fındings, and histopathology) helps determine the further evaluation of patients and should be used in concert with IHC stains and, when necessary, a gene expression profıle assay. Screening IHC stains should be performed initially on all cancers ( (Table 3 ), but even though these occult primary tumors may be present, not all the stains will be positive or negative as expected in the tumor cells of all these patients. The oncologist and pathologist need to talk about each patient. The clinical setting often suggests that other IHC stains may be useful, and IHC staining patterns may suggest additional directed specifıc clinical testing. It is not practical or possible to perform every possible IHC stain on the biopsy specimen. The initial clinicopathologic fındings narrow the possible additional testing to consider in each patient, including other imaging tests, directed IHC stains, and, in patients without a defınitive single tissue of origin diagnosis, a molecular profıle assay. 
TABLE 2. Additional Evaluation of Specific Patient Subsets Defined by Initial Diagnostic Evaluation

TABLE 3. Immunohistochemical Staining Profiles Supportive of a Single Primary Site in CUP*
Lung, adenocarcinoma/ large cell
CK7ϩ, CK20-, TTF-1ϩ
Lung neuroendocrine (small cell/large cell)
Chromograninϩ, Synaptophysin ϩ, TTF-1ϩ
Colorectal CK7-, CK20ϩ, CDX-2ϩ
Melanoma S100ϩ, Melan-Aϩ, HMB45ϩ
Renal RCCϩ, Vimentinϩ, CD10ϩ, PAX-8ϩ
Liver Hepar 1ϩ, CD10ϩ, CD13ϩ
Germ cell PLAPϩ and/or OCT-4ϩ
Thyroid (follicular/papillary) TTF-1ϩ, Thyroglobulinϩ
Abbreviations: CUP, cancer of unknown primary site; ER, estrogen receptor; PSA, prostatespecific antigen; RCC, renal cell carcinoma; PLAP, placental alkaline phosphatase; IHC, immunohistochemical, * When the above IHC profiles are present in an appropriate clinical context, CUP should be designated as CUP breast profile, CUP-non-small cell profile, CUP-colorectal profile, etc. In patients without a single tissue of origin diagnosis by IHC, a molecular profile assay should be obtained. If the biopsy specimen is very small, a molecular profile assay should be considered before multiple IHC stains are performed.
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A molecular profıle assay appears to complement IHC in many patients with CUP. The molecular assay should be considered initially in patients with only small biopsy specimens or malignant effusions since an ideal IHC evaluation is usually not feasible on these specimens. In those rare patients with only poorly differentiated cancers without a lineage clearly defıned by IHC, a molecular assay may be useful.
If an anatomic primary tumor site is not detected, the diagnosis of CUP is established. The IHC fındings and/or molecular profıling assay may establish the tissue of origin or primary site, but patients without a demonstrable anatomic primary site should still be considered within the clinicopathologic syndrome of CUP. However, patients with IHC and/or a molecular profıle assay highly suggesting a single primary site (CUP-colorectal, CUP-NSCLC, CUP-breast, etc.) should be treated with customized or site-specifıc treatment regimens, as recent data show their outcome is improved by such a tailored therapeutic approach. If future study verifıes a similar survival for these patients as their counterparts with advanced known carcinomas, these patients with CUP may be defınitely included as subsets of those same known advanced primary cancers.
In the past three decades several clinicopathologic "favorable subsets" (Table 4 ) of patients with CUP have been recognized (20% of all CUP). These patients have an improved prognosis with specifıc therapies, compared with the majority of the other patients (80%) with unfavorable prognostic features. 1 These patients have a relatively poor prognosis, despite the past results with empiric chemotherapy (combinations of "broad-spectrum" antineoplastic agents). These empiric regimens delivered to patients with unfavorable prognostic features has been the standard therapy for about 20 years, and have modestly improved their overall longterm survival (40% at 1 year, 20% at 2 years, 10% at 3 years, and beyond). However, their median survival has been only about 9 months. 19, 20 The administration of empiric therapeutic regimens to all patients now is no longer appropriate, since a diagnosis of the tissue of origin is possible in most patients.
Patients with several known advanced carcinomas (including breast, NSCLC, ovary, colon, prostate, esophagus, stomach, anal canal, renal, bladder/renal pelvis/ureter, rectum, uterine cervix, liver, melanoma, hepatocellular, head and neck, and others) have had improvements made in their systemic therapy in the past 10 years. For example, in advanced colorectal carcinomas, the median survival has increased from 8 months to nearly 2 years. Several targeted drugs are now also indicated for several of these patients. There are now recognized subsets of colon cancer (Kras wild type), breast cancer (HER2-neu amplifıed), and non-small cell lung cancer (epidermal growth factor receptor mutation, anaplastic lymphoma kinase rearrangement, R0S1 rearrangement), which respond and benefıt substantially from targeted agents.
A subset of patients with CUP with a colorectal profıle (recognized by IHC and/or molecular profıle assay) has been treated with site-specifıc colorectal therapy. Their response rate and survival appear similar to known patients with advanced colorectal cancer. 7, [21] [22] [23] When these patients were treated with empiric paclitaxel and carboplatin, the treatment did quite poorly with low-response rates and poor survival. This colorectal CUP subset may be recognized by IHC marker stains 21 or molecular profıling assays, and their prognosis is considerably better when they receive site-directed therapy, rather than empiric chemotherapy. 22, 23 The CUPcolorectal subset is an example of colorectal carcinoma presenting as CUP, and their prognosis also appears similar to known advanced colorectal cancer after appropriate therapy.
Renal and hepatocellular carcinoma represent examples of solid tumors that targeted drugs improve overall patient survival and cytotoxic chemotherapy are not useful. Chemotherapy and/or targeted drugs have also improved the survival for patients with selected subsets of non-small cell lung cancer, colorectal carcinomas, breast carcinomas, melanoma, gastrointestinal stromal tumors, basal cell carcinoma, and medullary carcinoma of the thyroid. Customized therapy for the specifıc type of cancer is much more important now than a decade ago. Therefore, recognition of the tissue of origin in CUP is also more important. The era of empiric-based chemotherapy for CUP is ending in favor of site-specifıc treatment based on accurate identifıcation of the tissue of origin. The ability to frequently diagnose the tissue of origin in CUP is reshaping the fıeld and producing a new paradigm of patient management. The clinical landscape has changed dramatically in the last several decades (Table 5) .
CONCLUSION
The ability to make a diagnosis of the occult primary cancer or tissue of origin in CUP has greatly improved by the use of panels of IHC stains and molecular profıling assays. Molecular profıle assays are relatively accurate, complement standard pathology, and frequently are diagnostic when IHC is inconclusive. A large prospective study of patients with CUP was recently published in which patients were treated with site-specifıc therapy based on the molecular assay diagnoses. 15 The median survival was improved, and several subsets of diagnosed patients had survivals similar to their counterparts with known advanced cancer. In patients with responsive tumor types diagnosed by molecular assay, their survival was signifıcantly superior to those diagnosed with lessresponsive tumor types. Site-specifıc and molecular-targeted therapies continue to improve for patients with several advanced solid tumors, and these therapies can be administered to patients with CUP, specifıcally defıned by IHC profıles and/or molecular profıle assays. Clinical oncology is an ever changing and fluid fıeld, and useful new technology is often slow to be incorporated into clinical practice. The use of molecular profıle assays in CUP represents an improved diagnostic test, but requires clinical judgment to interpret the results. This is similar for any other new technology in medicine. Additional clinical trials are necessary to better defıne the precise role of molecular diagnosis in CUP. Genomic investigations may also eventually fınd specifıc CUP genetic abnormalities which may explain the biology and perhaps provide additional clues to improve therapy. Empiric chemotherapy regimens in CUP have a role only in a small percentage of patients with CUP in whom the tissue of origin remains uncertain. As expected, patients with the more responsive tumor types will benefıt most from discovery of their tissue of origin. A large minority of patients will not currently benefıt from sitedirected therapy, since effective therapy for their tumor types is not yet available. Confıdence in the diagnosis of the tissue of origin will allow these patients to receive more effective therapy as the standard therapies for these tumor types improve. Patients with CUP will be treated in the future with therapy indicated for their specifıc tumor type or with other molecular targeted agents directed at critical genetic aberrations found in their tumors, regardless of their primary tumor site. 
